Amenamevir - Maruho
Alternative Names: Amenalief; ASP-2151; M-5220; M5220BLatest Information Update: 22 Dec 2021
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Maruho
- Class Amides; Antivirals; Oxadiazoles; Small molecules
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Herpes zoster
- Phase III Herpes labialis; Herpes simplex virus infections
Most Recent Events
- 03 Apr 2021 Maruho completes a phase III trial in Herpes labialis in Japan (JapicCTI-194954)
- 01 Dec 2018 Maruho plans a phase I trial (Haemodialysis patients) in Japan (JapicCTI184242)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(In volunteers) in United Kingdom (PO, Tablet)